Login   |   Register
Cover Image

HLA-mismatched hematopoietic stem cell tranplantation for pediatric solid tumors

Andrea Pession, Riccardo Masetti, Corinne Di Leo, Monica Franzoni, Arcangelo Prete

Authors information
  • Riccardo Masetti
    Affiliation not present.
  • Corinne Di Leo
    Affiliation not present.
  • Monica Franzoni
    Affiliation not present.
  • Arcangelo Prete
    Affiliation not present.


Even if the overall survival of children with cancer is significantly improved over these decades, the cure rate of high-risk pediatric solid tumors such as neuroblastoma, Ewing’s sarcoma family tumors or rhabdomiosarcoma remain challenging. Autologous hematopoietic stem cell transplantation (HSCT) allows chemotherapy dose intensification beyond marrow tolerance and has become a fundamental tool in the multimodal therapeutical approach of these patients. Anyway this procedure does not allow to these children an eventfree survival approaching more than 50% at 5 years. New concepts of allogeneic HSCT and in particular HLA-mismatched HSCT for high risk solid tumors do not rely on escalation of chemo therapy intensity and tumor load reduction but rather on a graft-versus-tumor effect. We here report an experimental study design of HLA-mismatched HSCT for the treatment of pediatric solid tumors and the inherent preliminary results.

Full Text:

Submitted: 2011-06-17 18:52:26
Published: 2011-06-17 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM



Pediatric Reports [eISSN 2036-7503] is an Open Access, peer-reviewed journal published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
© PAGEPress 2008-2015     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185